Press release regarding audited financial results for year ended March 31, 2025.
FERMENTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fermenta Biotech reported a strong operational turnaround for FY25. Consolidated revenue rose 39% year-on-year to INR 481.3 crore, EBITDA jumped 209% to INR 121.6 crore, and net profit stood at INR 76.4 crore versus a loss in the previous year. Excluding the real estate business, core revenue grew 57% to INR 427.0 crore. Human nutrition volumes grew 48% and animal nutrition volumes grew 24% over FY24. The company launched Vitadee Green™, described as the world's first pharmacopeial-grade plant-based Vitamin D3, and its German and US subsidiaries posted sharp revenue growth of 412% and 81% respectively.
The results signal a clear earnings recovery from the prior year's loss, with strong margin expansion and growth across geographies. For shareholders, this is a positive development that could support the stock price, though Q4 sequential decline in EBITDA and revenue warrants attention.